A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Solid Tumor
Interventions
DRUG

BGB-R046

Intravenous administration

DRUG

Tislelizumab

Intravenous administration

Trial Locations (8)

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

250013

RECRUITING

Jinan Central Hospital, Jinan

272000

RECRUITING

Jining No Peoples Hospital West Branch, Jining

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

530021

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY